Nuwellis Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Global X NASDAQ 100 Covered Call ETF is far larger — about 3859.1× Nuwellis Inc's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| NUWE | QYLD | |
|---|---|---|
Market Cap | $2.20M | $8.49B |
Volume | 121,544 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $146.65 | $18.68 |
52-Week Low | $0.68 | $16.70 |
Typical Hold Time | 26 Days | 51 Days |
Enterprise Value | -$1.52M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF maintains a consistent monthly dividend payout of $0.18, providing an attractive yield for income-focused investors. Technical indicators present a mixed picture with an overall bullish signal from moving averages but bearish momentum from oscillators, while RSI levels suggest potential overbought conditions. Recent news highlights QYLD's role as a covered call ETF generating income through Nasdaq 100 options strategies.
The outlook for QYLD remains focused on income generation rather than capital appreciation, with the covered call strategy capping upside potential during market rallies. Key risks include declining option premiums, principal erosion over time, and tax treatment uncertainties. Investors should weigh the high monthly yield against the trade-off of limited participation in Nasdaq 100 growth, making it suitable for income needs but less ideal for long-term capital growth objectives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →